细胞角蛋白20的表达与晚期(pT4)膀胱尿路上皮癌的分期进展和不良预后有关

IF 2.8 4区 医学 Q2 PATHOLOGY
Paul Giacomo Bruch , Henning Plage , Sebastian Hofbauer , Kira Kornienko , Sarah Weinberger , Florian Roßner , Simon Schallenberg , Martina Kluth , Maximilian Lennartz , Niclas C. Blessin , Andreas H. Marx , Henrik Samtleben , Margit Fisch , Michael Rink , Marcin Slojewski , Krystian Kaczmarek , Thorsten Ecke , Steffen Hallmann , Stefan Koch , Nico Adamini , Sefer Elezkurtaj
{"title":"细胞角蛋白20的表达与晚期(pT4)膀胱尿路上皮癌的分期进展和不良预后有关","authors":"Paul Giacomo Bruch ,&nbsp;Henning Plage ,&nbsp;Sebastian Hofbauer ,&nbsp;Kira Kornienko ,&nbsp;Sarah Weinberger ,&nbsp;Florian Roßner ,&nbsp;Simon Schallenberg ,&nbsp;Martina Kluth ,&nbsp;Maximilian Lennartz ,&nbsp;Niclas C. Blessin ,&nbsp;Andreas H. Marx ,&nbsp;Henrik Samtleben ,&nbsp;Margit Fisch ,&nbsp;Michael Rink ,&nbsp;Marcin Slojewski ,&nbsp;Krystian Kaczmarek ,&nbsp;Thorsten Ecke ,&nbsp;Steffen Hallmann ,&nbsp;Stefan Koch ,&nbsp;Nico Adamini ,&nbsp;Sefer Elezkurtaj","doi":"10.1016/j.yexmp.2023.104860","DOIUrl":null,"url":null,"abstract":"<div><p>Cytokeratin 20 (CK20) expression is limited to umbrella cells in the normal urothelium. Since CK20 is often upregulated in neoplastic urothelial cells including dysplasia and carcinoma in situ, immunohistochemical CK20 analysis is often used for the assessment of bladder biopsies. CK20 expression is a feature of luminal bladder cancer subtype, but its prognostic relevance is disputed. In this study, we investigated CK20 on &gt;2700 urothelial bladder carcinomas in a tissue microarray format by immunohistochemistry. Cytoplasmic and membranous CK20 staining was seen in 1319 (51.8%) cancers. The fraction of CK20 positive and especially strongly positive cases increased from pTaG2 low grade (44.5% strongly positive) and pTaG2 high grade (57.7%) to pTaG3 high grade (62.3%; <em>p</em> = 0.0006) but was lower in muscle-invasive (pT2–4) carcinomas (51.1% in all pTa vs. 29.6% in pT2–4; <em>p</em> &lt; 0.0001). Within pT2–4 carcinomas, CK20 positivity was linked to nodal metastasis and lymphatic vessel invasion (p &lt; 0.0001 each) and to venous invasion (<em>p</em> = 0.0177). CK20 staining was unrelated to overall patient survival if all 605 pT2–4 carcinomas were jointly analyzed but subgroup analyses revealed a significant association of CK20 positivity with favorable prognosis in 129 pT4 carcinomas (<em>p</em> = 0.0005). CK20 positivity was strongly linked to the expression of GATA3 (<em>p</em> &lt; 0.0001), another feature of luminal bladder cancer. The combined analysis of both parameters showed best prognosis for luminal A (CK20+/GATA3+, CK20+/GATA3-) and worst outcome for luminal B (CK20−/GATA3+) and basal/squamous (CK20−/GATA3-) in pT4 urothelial carcinomas (<em>p</em> = 0.0005). In summary, the results of our study demonstrate a complex role of CK20 expression in urothelial neoplasms including neoexpression in pTa tumors, a subsequent loss of CK20 expression in a subset of tumors progressing to muscle-invasion, and a stage dependent prognostic role in muscle-invasive cancers.</p></div>","PeriodicalId":12176,"journal":{"name":"Experimental and molecular pathology","volume":"131 ","pages":"Article 104860"},"PeriodicalIF":2.8000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder\",\"authors\":\"Paul Giacomo Bruch ,&nbsp;Henning Plage ,&nbsp;Sebastian Hofbauer ,&nbsp;Kira Kornienko ,&nbsp;Sarah Weinberger ,&nbsp;Florian Roßner ,&nbsp;Simon Schallenberg ,&nbsp;Martina Kluth ,&nbsp;Maximilian Lennartz ,&nbsp;Niclas C. Blessin ,&nbsp;Andreas H. Marx ,&nbsp;Henrik Samtleben ,&nbsp;Margit Fisch ,&nbsp;Michael Rink ,&nbsp;Marcin Slojewski ,&nbsp;Krystian Kaczmarek ,&nbsp;Thorsten Ecke ,&nbsp;Steffen Hallmann ,&nbsp;Stefan Koch ,&nbsp;Nico Adamini ,&nbsp;Sefer Elezkurtaj\",\"doi\":\"10.1016/j.yexmp.2023.104860\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Cytokeratin 20 (CK20) expression is limited to umbrella cells in the normal urothelium. Since CK20 is often upregulated in neoplastic urothelial cells including dysplasia and carcinoma in situ, immunohistochemical CK20 analysis is often used for the assessment of bladder biopsies. CK20 expression is a feature of luminal bladder cancer subtype, but its prognostic relevance is disputed. In this study, we investigated CK20 on &gt;2700 urothelial bladder carcinomas in a tissue microarray format by immunohistochemistry. Cytoplasmic and membranous CK20 staining was seen in 1319 (51.8%) cancers. The fraction of CK20 positive and especially strongly positive cases increased from pTaG2 low grade (44.5% strongly positive) and pTaG2 high grade (57.7%) to pTaG3 high grade (62.3%; <em>p</em> = 0.0006) but was lower in muscle-invasive (pT2–4) carcinomas (51.1% in all pTa vs. 29.6% in pT2–4; <em>p</em> &lt; 0.0001). Within pT2–4 carcinomas, CK20 positivity was linked to nodal metastasis and lymphatic vessel invasion (p &lt; 0.0001 each) and to venous invasion (<em>p</em> = 0.0177). CK20 staining was unrelated to overall patient survival if all 605 pT2–4 carcinomas were jointly analyzed but subgroup analyses revealed a significant association of CK20 positivity with favorable prognosis in 129 pT4 carcinomas (<em>p</em> = 0.0005). CK20 positivity was strongly linked to the expression of GATA3 (<em>p</em> &lt; 0.0001), another feature of luminal bladder cancer. The combined analysis of both parameters showed best prognosis for luminal A (CK20+/GATA3+, CK20+/GATA3-) and worst outcome for luminal B (CK20−/GATA3+) and basal/squamous (CK20−/GATA3-) in pT4 urothelial carcinomas (<em>p</em> = 0.0005). In summary, the results of our study demonstrate a complex role of CK20 expression in urothelial neoplasms including neoexpression in pTa tumors, a subsequent loss of CK20 expression in a subset of tumors progressing to muscle-invasion, and a stage dependent prognostic role in muscle-invasive cancers.</p></div>\",\"PeriodicalId\":12176,\"journal\":{\"name\":\"Experimental and molecular pathology\",\"volume\":\"131 \",\"pages\":\"Article 104860\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental and molecular pathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0014480023000114\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and molecular pathology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0014480023000114","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 2

摘要

细胞角蛋白20 (CK20)的表达仅限于正常尿路上皮的伞状细胞。由于CK20在包括不典型增生和原位癌在内的肿瘤尿路上皮细胞中经常上调,因此免疫组织化学CK20分析经常用于膀胱活检的评估。CK20表达是腔内膀胱癌亚型的一个特征,但其与预后的相关性尚存争议。在本研究中,我们通过免疫组织化学的组织芯片形式研究了CK20对2700例尿路上皮性膀胱癌的影响。1319例(51.8%)肿瘤细胞质和膜性CK20染色。CK20阳性和强阳性病例的比例从pTaG2低级别(强阳性44.5%)和pTaG2高级别(57.7%)增加到pTaG3高级别(62.3%);p = 0.0006),但在肌肉浸润性(pT2-4)癌中较低(所有pTa为51.1%,pT2-4为29.6%;p & lt;0.0001)。在pT2-4癌中,CK20阳性与淋巴结转移和淋巴管侵袭有关(p <0.0001)和静脉侵入(p = 0.0177)。如果对所有605例pT2-4癌进行联合分析,CK20染色与患者总体生存率无关,但亚组分析显示,129例pT4癌中CK20阳性与良好预后显著相关(p = 0.0005)。CK20阳性与GATA3的表达密切相关(p <0.0001),这是腔内膀胱癌的另一个特征。这两个参数的综合分析显示,pT4尿路上皮癌中,管腔A (CK20+/GATA3+、CK20+/GATA3-)预后最好,管腔B (CK20−/GATA3+)和基底/鳞状(CK20−/GATA3-)预后最差(p = 0.0005)。总之,我们的研究结果证明了CK20表达在尿路上皮肿瘤中的复杂作用,包括pTa肿瘤中的新表达,CK20在一部分肿瘤进展为肌肉侵袭的随后表达缺失,以及在肌肉侵袭性癌症中的分期依赖预后作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder

Cytokeratin 20 (CK20) expression is limited to umbrella cells in the normal urothelium. Since CK20 is often upregulated in neoplastic urothelial cells including dysplasia and carcinoma in situ, immunohistochemical CK20 analysis is often used for the assessment of bladder biopsies. CK20 expression is a feature of luminal bladder cancer subtype, but its prognostic relevance is disputed. In this study, we investigated CK20 on >2700 urothelial bladder carcinomas in a tissue microarray format by immunohistochemistry. Cytoplasmic and membranous CK20 staining was seen in 1319 (51.8%) cancers. The fraction of CK20 positive and especially strongly positive cases increased from pTaG2 low grade (44.5% strongly positive) and pTaG2 high grade (57.7%) to pTaG3 high grade (62.3%; p = 0.0006) but was lower in muscle-invasive (pT2–4) carcinomas (51.1% in all pTa vs. 29.6% in pT2–4; p < 0.0001). Within pT2–4 carcinomas, CK20 positivity was linked to nodal metastasis and lymphatic vessel invasion (p < 0.0001 each) and to venous invasion (p = 0.0177). CK20 staining was unrelated to overall patient survival if all 605 pT2–4 carcinomas were jointly analyzed but subgroup analyses revealed a significant association of CK20 positivity with favorable prognosis in 129 pT4 carcinomas (p = 0.0005). CK20 positivity was strongly linked to the expression of GATA3 (p < 0.0001), another feature of luminal bladder cancer. The combined analysis of both parameters showed best prognosis for luminal A (CK20+/GATA3+, CK20+/GATA3-) and worst outcome for luminal B (CK20−/GATA3+) and basal/squamous (CK20−/GATA3-) in pT4 urothelial carcinomas (p = 0.0005). In summary, the results of our study demonstrate a complex role of CK20 expression in urothelial neoplasms including neoexpression in pTa tumors, a subsequent loss of CK20 expression in a subset of tumors progressing to muscle-invasion, and a stage dependent prognostic role in muscle-invasive cancers.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.90
自引率
0.00%
发文量
78
审稿时长
11.5 weeks
期刊介绍: Under new editorial leadership, Experimental and Molecular Pathology presents original articles on disease processes in relation to structural and biochemical alterations in mammalian tissues and fluids and on the application of newer techniques of molecular biology to problems of pathology in humans and other animals. The journal also publishes selected interpretive synthesis reviews by bench level investigators working at the "cutting edge" of contemporary research in pathology. In addition, special thematic issues present original research reports that unravel some of Nature''s most jealously guarded secrets on the pathologic basis of disease. Research Areas include: Stem cells; Neoangiogenesis; Molecular diagnostics; Polymerase chain reaction; In situ hybridization; DNA sequencing; Cell receptors; Carcinogenesis; Pathobiology of neoplasia; Complex infectious diseases; Transplantation; Cytokines; Flow cytomeric analysis; Inflammation; Cellular injury; Immunology and hypersensitivity; Athersclerosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信